Therapeutic antibody agreement for AbCellera & Gilead

Acquisition sees Abcam enter cell editing market
Credit: Matej Kastelic

AbCellera is supporting the discovery of therapeutic antibody candidates for infectious diseases by entering into an agreement with Gilead Sciences.

The agreement will see AbCellera apply its expertise in single-cell screening of natural immune sources to generate rich panels of antibody candidates for evaluation by Gilead.

AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.

Leveraging a suite of proprietary technologies, AbCellera’s team can interrogate millions of single B cells in a campaign, an approach that has proven successful in identifying low-frequency subsets of antibodies among large and diverse panels of binders.

In this collaboration, AbCellera will be looking for ultra-rare antibodies with specific properties defined by Gilead, a challenging problem that demands screening depths that are orders of magnitude higher than alternative discovery approaches.